Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KOPM: Ketamine in Polytraumatized Orthopedic Patients
NCT06903819Phase 4Recruiting
- Sponsor
- Texas Tech University Health Sciences Center
- Start
- Nov 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of ketamine in postoperative pain, major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) (2 arms), sponsored by Texas Tech University Health Sciences Center. Primary endpoint: Pain Intensity at 6 months. Started Nov 2025; status: recruiting.
02
Drugs
ketamine
03
Conditions
postoperative painmajor depressive disorder (MDD)post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT06903819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06903819.